DNA

Electromedical Provides Update to Shareholders

Electromedical (EMED), a Leader in Bioelectronic Medical Devices, Updates Shareholders on Recent Achievements and Strategic AdvancementsSCOTTSDALE, AZ / ACCESSWIRE /…

5 months ago

FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services

MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced that its recently acquired subsidiary,…

5 months ago

Healthcare Sector Sees Steady Rise in VC Investment and Fundraising; Silicon Valley Bank Releases 14th Edition of Mid-Year Healthcare Investments and Exits Report

2024 shaping up to be a strong year for biopharma SAN FRANCISCO, Aug. 7, 2024 /PRNewswire/ -- In the first half…

5 months ago

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…

5 months ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency…

5 months ago

Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country

Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06,…

5 months ago

Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens

High-throughput, high-content imaging-based assay developed to screen convalescent sera for neutralizing antibodies to SARS-CoV-2 variants Study highlights Tonix’s internal R&D…

5 months ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment…

5 months ago

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program…

5 months ago